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ever be administered to any patient because of the
risk that the anaesthetic agent or the technique may
be responsible for the death of the patient. This risk
is 4,000 times greater than the risk of death from an
anaesthetic explosion. A nicely calculated balancing
of the risks. involved in any anaesthetic should deter-
mine the choice of agent and technique, but the weight
of available evidence suggests that those who will
never use a flammable anaesthetic agent are deterred,
not so much by the thought of what might happen
to the patient, but by the thought of what might happen
to themselves.
For those who feel that the elementary precautions
to be observed in the use of flammable anaesthetic
agents, which can be deduced from the discussion in
this article, constitute insufficient protection, it is now
possible to acquire a piece of apparatus known as an
'Explosimeter'.* This apparatus will indicate quickly
and accurately whether a small gas-sample presented
to it is capable of being ignited or exploded. With
this apparatus it is possible, at any time, to monitor
the anaesthetic atmosphere being inhaled by the
patient.
* For example, that produced by Messrs. Mines Safety Ap-
pliances.
SUMMARY
The risk of death from an explosion during any anaes-
thetic is of the order of I in n million while the risk
of death from the anaesthetic- itself is 2:reater than
I in 2,000. -
The conditions required for explosion of anaesthetic
atmospheres are discussed and a case is presented to
emphasize that explosions are usually the result of
failure to observe simple precautions.
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Mephenesin was introduced in -1951 as a muscle relaxant.
It was found to act mainly on the spinal cord, but also
on the basal ganglia and the brain stem. Favourable
comments on its action have been published in cases
of rheumatoid arthritis, fibrositis, spastic paralysis,
disseminated sclerosis, and other conditions.
Since 1954 mephenesin (Tolserol, Squibb) has been
replaced by mephenesin carbamate (Tolseram) as
being more efficacious and less toxic. Reports of its
value have appeared from Engler1 ,2 in severe spastic
disorders present from birth, frdm Larkin 3 in fibrositis,
and from Marsha1l4 in disseminated sclerosis. On the
other hand Fasser 5 has stated that 'Tolserol and other
related drugs have been found to possess no value or
very little indeed' in cerebral palsy.
It was therefore decided to test its efficacy on 10
spastic patients in this Institution. All are certified
mental defectives of various grades, and all suffer from
severe spastic disorders of various types. .
Dosage. The drug is available as 0- 5 g: tablets and
was administered in a little milk immediately after
meals. In adults the initial daily (divided) dose was 6 g.,
and this dosage was maintained for 4 weeks if the patient
responded. Where no response was obtained the daily
dose was raised to 9 g. In children the initial dose was
1· 5-3 g. daily, according to age, which was increased
to 4· 5 g. and later to 6 g. where no initial response
was obtained. Where no response was obtained at
the end of 3 weeks treatment was stopped. In the
other cases tailing off was begun at the end of the
4th week, when the dosage was halved. The following
week it was halved again, and this reduction continued
until adults were getting 1 g. per day and children
0·5 g. per day as maintenance doses.
Side-effects. These were mild. and transient. One
patient vomited, two showed drowsiness, one showed
marked pallor, and one had a sense of weakness and
loss of power in the spastic limbs. One patient com- •
plained of pains in the affected muscle-groups, and
another of giddiness of short duration shortly after
swallowing his tablets. Two patients showed a marked
increase in appetite during treatment. In no case did
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treatment have to be suspended because of undesirable
side-effects.
PATIENTS
The patients were selected entirely on the basis of
suffering from severe forms of spastic paralysis without
taking into account the cause of the paralysis. Their
spasticity was due to such varied conditions as cerebral
palsy, localized upper-motor-neurone lesions, and
encephalitis. Their mental states varied fFom idiocy
to high-grade feeblemindedness.
All patients were given a careful neurological exami-
nation before treatment was begun, and were re-
examined at weekly intervals during the period of
treatment. One of the difficulties encountered was
the assessment of the amount of spasticity· present.
Engler2 measured the range of movement in the joints
of his patients before treatment, and was thus able to
record· any subsequent improvement. After consultation
with an orthopaedic surgeon and a physiotherapist we
der.ided that there was no truly reliable objective method
of measuring the amount of spasticity, and we decided
to rely on our own subjective impressions of the amount
of spasticity present. We recorded this in our notes as
ahsent (-), minimal (±), mild (+), severe (+ +),
or very severe (+ + + ).
None of the cases had had any form of physiotherapy
in the institution before Tolseram was administered,
although simple forms of this were initiated in several
cases once a noticeable improvement had been demon-
strated.
A brief description of the individual cases and their
- responses will now be given:
1. Male aged 19 years
Spasticity wa5 first noticed at 6 months. At 4 years he could no
longer stand or walk, and was treated for a short time at Uplands
Orthopaedic Home, Pietermaritzburg.
Before Tolseram treatment was begun he showed severe spasticity
of all the limbs and neck, he grimaced continually, his speech
was quite unintelligible, he had difficulty in swaJlowing, and
salivation was marked. He could only move around by sliding
on his buttocks on a piece of leather.
At the end of the 1st week of treatment spasticity was no 10nEer
present in the neck, and it was markedly diminished in the limbs.
He could now feed himself, and swallowed with less difficulty.
Grimacing and salivation were noticeably diminished.
At the end of the 2nd week grimacing and salivation were
absent, and spasticity in the arms and legs had further diminished.
He was now able to walk a few steps with assistance-something
he had not· done for many years. At the end of the 3rd week
he could walk fairly well while pushing a wheel-chair. His appetite
had increased prodigiously and his general physical condition
had improved noticeably. By the end of the 4th week he was
generally happier and more cheerful, and was easier to manage.
His speech was clearer and more intelligible. This improvement
has been sustained on the lowered maintenance dose after 4 weeks.
2. lv/ale aged 10 years
Had encephalitis at 2 years. Three months later he developed
numerous attacks of petit-mal and signs of Parkinsonism.
Before treatment he showed severe spasticity of all the limbs,
marked tremor in the arms, and gross incoordination. Patellar
and ankle clonus were present and his plantar reflexes were extensor.
Speech was markedly slurred and indistinct, and salivation was
severe. He could not sit up without assistance, could not walk and
had to be fed, and his personal habits were faulty.
At the end of the 1st week of treatment rigidity in the arms and
legs was considerably diminished, tremor of the arms had ceased,
and salivation was noticeably less. The ankle clonus had dis-
appeared, although knee clonus was still present.
At the end of the 3rd week spasticity in all limbs was minimal,
and knee clonus was absent. He could now sit up unassi ted, and
could feed himself reasonably well. When he wished to urinate
he asked for the bottle. At the end of the 4th week his soeech was
much more distinct and he asked to be taken to the lavatory to
defaecate, i.e. his personal habits were now clean. He could walk
the length of the ward with minimal support. This improvement
has persisted after 4 weeks on a low maintenance dose.
3. Male aged 24 years
At 10 years of age he suddenly lost the use of his left arm and leg
and by the time he was 15 he showed the typical features of a
spastic hemiplegia. In 1955 all the toes on his left foot were ampu-
tated because of a plantar flexion deformity which hindered
walking.
Before treatment was begun he showed marked spastic rigidity
of the left arm and leg. The arm was kept fully flexed at the elbow
and showed severe athetotic movements. Coordination was poor
and he could perform the grossest movements only, with difficulty.
At the end of the 1st week of treatment there was no change
apparent on physical examination, but the patient (a high-grade
defective) stated his left arm felt more relaxed. At the end of the
2nd week the arm was noticeably less spastic and was not kept
fully flexed any longer. He could open his left hand voluntarily,
and could pick up a small pin off the table without undue difficulty.
The leg showed diminished spasticity, and he stated he now walked
betier and ·with less discomfort.
At the end of the 3rd week the athetoid movements in the arm
were hardly noticeable, while spasticity had decreased still further.
He stated he could now walk 'a hundred times bener', and the leg
showed no spasticity on examination. At this stage simple physio-
therapy for the left arm was begun. At the end of the 4th week
the arm was carried practically fully extended, and he had good
control over it. He felt his walking was still improving. After
4 more weeks on only a maintenance dose improvement was
sustained.
4. Male aged 47 years
His condition set in at 3 years after a febrile il!ness. .
Before treatment he showed moderate spasticity of arms, legs
and neck. He walked with difficulty, ate slowly and spilt a good
deal of hi5 food. Salivation was marked. At the end of 2 weeks of
treatment there wa" some diminution in spasticity. At the end of
the 3rd week there was no further improvement despite increased
dosage, and treatment was discontinued.
5. Male aged 53 years
He was normal til! 14, when he developed epileptic seizures
followed by spastic paralysis of both legs. For the last 18 years
he has been confined to a wheel-chair. Before treatment his legs
showed moderate spasticity, with bilateral patellar clonus and
a positive Babinski. He had bilateral club-foot. At the end of the
2nd week of treatment spasticity had disappeared and clonus was
absent. At the end of another week the patient stated that his
legs felt more relaxed. During the 4th week of treatment he made
an attempt to walk which was unsuccessful largely owing to the
gross fixed deformity of his feet. He is more placid and happier,
and is now adjusting we!! to vocational training, though still
confined to his wheel-chair.
6. ~Male aged 23 years
No previous history is available. Before treatment was begun he
showed a right-sided hemiplegia, with moderate spasticity of the
arm and leg, patellar clonus and a positive Babinski. At the end
of the 1st week of treatment the patellar clonus was absent, but
there was no further improvement in spite of increased dosage of
Tolseram. Treatment was di~continued at the end of the 3rd week.
7. Male aged 4 years
A case of apparently congenital spastic quadriplegia. Before
treatment he showed severe spasticity of all the limbs and was
completely helpless. There was marked salivation, which dimi-
nished after one week of treatment. As no further change occurred
the dosage was increased at the end of the 2nd week. 10 funher
improvement was noted on examination, but the nursing staff
reported that he moved around more freely in his cot. The dosage
was increased again but with no further improvement, and treat-
ment was discontinued.
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8. Male aged 6 years
He had basal meningitis at 2 months, followed by hydrocephalus
and spastic paralysis. A craniotomy was performed by a neuro-
surgeon in Johannesburg with no improvement.
Before treatment was begun he showed spasticity of arms, legs
.and neck, and was completely helpless. At the end of the 1st
week there was diminished spasticity but no further improvement
resulted even after the dose had been increased twice. Treatment
was then discontinued.
9. Female aged 5 years
Spastic quadriplegia and epilepsy present since birth. Before
treatment she showed moderate spasticity of arms, legs and neck,
and she was completely helpless. As treatment brought about no
change in spite of 2 increases in dosage, it was discontinued in
the 4th wee~.
10. .Male aged 5 years
A boy who developed normally until he was 18 months old,
when he suddenly became comatose and remained unconscious
for a week. "''hen he regained consciousness he was unable to
walk or talk and showed spastic paralysis. An air-encephalogram
showed right fronto-parietal cortical atrophy.
Before treatment was begun he showed spasticity of arms and
legs, most marked on the left, and neck rigidity. He used only his
right hand, was unable to walk, and grimaced continually. At the
end of a week's treatment the grimacing was less marked and the
spasticity of the neck and limbs had diminished. At the end of the
2nd week there was no further improvement on examination, but he
could now stand and take a few steps with assistance. At the end
of the 3rd week spasticity in the left leg and arm had diminished
still further. He could now kneel in his cot unassisted. Further
treatment produced no other improvement, but the improvement
gained has been sustained after 4 weeks on a maintenance dose.
CONCLUSIONS
Of the 10 cases treated with Tolseram, in only one case
(no. 9) could it be said that there was no response at
all, although in 4 others (nos. 4, 6, 7, and 8) improvement
was only transient and the treatment was ultimately
discontinued.
The other 5 cases showed sufficient improvement to
warrant continuation of maintenance doses of the drug,
while in 3 cases (Nos. 1, 2 and 3) improvement can
fairly be described as striking. One therefore feels
justified in stating that Tolseram is worthy of a trial
in all forms of spastic paralysis, more especially as it
appears to be quite safe and unaccompanied by any
serious side-effects.
SUMMARY
Mephenesin carbamate has been administered to 10
cases of spastic paralysis for a period of 8 weeks. Five
cases showed some improvement and, of these, :3
showed a striking improvement.
We are grateful to Dr. I. R. Vermooten, Commissioner for
Mental Hygiene, for permission to publish this paper, and to
Messers. E. R. Squibb and Sons, Johannesburg, for a supply of
Tolseram.
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AMOEBIC PERICARDITIS: A CASE REPORT
CASE REPORT
An African male 29 years old was admitted to King Edward VIII
Hospital, Durban, on 12 November 1954 complaining of severe
pain in the left hypochondrium and slight non-productive cough,
for 6 weeks. The pain had become progressively worse since its
onset. There was no history of previous dysentery or other
significant illness.
Examination. The patient, a well built and well nourished man.
was acutely ill and distressed. His temperature was 103°F. The
jugular venous pressure was not raised and there was no oedema.
There was a very tender fluctuating swelling of the anterior ab-
dominal wall in the left hypochondrium extending down from the
costal margin and about 2t inches in diameter. The surface
of the swelling was smooth, with normal overlying skin.
G. GORDON, M.B., CH.B. (CAPE TOWN)
Former Medical Registrar, King Edward VIII Hospital, Durban
this type' may easily be confused with pericarditis
from other causes, especially tuberculous pericarditis.
The serous effusion may become purulent.
3. Sudden rupture of the liver abscess into the
pericardium may occur, with suppurative pericarditis.
This may present like· the case described' below, but
sudden collapse and rapid death may occur.
The following case-history illustrates some typical
clinical features of suppurative amoebic pericarditis.
Pericarditis is a rare complication of amoebic abscess
of the liver. Reviewing the literature, Carter and
Korones1 reported a total of only 44 proved cases of
suppurative amoebic pericarditis for the period 1885
to 1950. The mortality rate was very high, and diagnosis
during life was made in only 2 cases, one of which
recovered. In an unselected series of 2,000 autopsies
performed at King Edward vrn Hospital during a
5-year period 1950-55, 8" cases of suppurative amoebic
pericarditis were found. The number of autopsies
performed was less than 10 %of all deaths.
The condition may present in the following ways:
1. Cases of liver abscess with which is associated a
pericardial friction-rub or electrocardiographic changes
suggestive of pericarditis. There is no pericardial
effusion or cardiac distress and the condition clears
up as the liver abscess is treated. This is probably not
very uncommon with abscesses of the left lobe of the
liver.
2. As a serous (sympathetic) pericardial effusion
without frank rupture of the abscess into the pericardium.
When the diagnosis of liver abscess is not apparent
